Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
AnaptysBio IncANAB-4.0019.3912.37-5.91-214.89%-29.92%37.36$29.53$209.0042,442$21.60

Detail of AnaptysBio Inc

 
CEO
Mr. Daniel R. Faga
Employees
102
Industry
Biotechnology
Sector
Healthcare
Market cap
$591M

Company details

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Revenue
Revenue (Rev)
$30.47M
AnaptysBio Inc
ANAB • XNGS • US
$21.60
+5.43 (33.52%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$5.40
Margin profit
0.00%
52 week low
$13.85
52 week high
$40.419998
50-day simple moving average
$28.98
200-day simple moving average
$29.53
Percent held by insiders
1.75%
Percent held by institutions
101.40%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ANAB +23.67%
eps change
ANAB 0.00%